Advertisement

Leukemias pp 213-218 | Cite as

Cellular Pharmacokinetics of Daunomycin in Human Leukemic Blasts In Vitro and In Vivo

  • M. E. Scheulen
  • B. Kramer
  • M. Skorzec
  • W. K. Reich
Conference paper

Abstract

The description of a decrease in the intracellular accumulation of a number of cytostatics, such as anthracyclines, vinca alkaloids, epipodophyllotoxins, and actinomycin D, in drug-resistant malignant cells, which was first demonstrated for colchicine in Chinese hamster ovary cells [4], has substantially contributed to the understanding of “multidrug resistance” [6]. This process is caused by an energy-dependent outward pump in connection with the expression of the 170000-Da plasma membrane glycoprotein P170 [21].

Keywords

Acute Myeloid Leukemia Chinese Hamster Ovary Cell Acute Myelogenous Leukemia Intracellular Accumulation Cytosine Arabinoside 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Büchner T, Urbanitz D, Hiddemann W, Rühl H, Ludwig WD, Fischer J, Aul HC, Vaupel HA, Kuse R, Zeile G, Nowrousian MR, König HJ, Walter M, Wendt FC, Sodomann H, Hossfeld DK, von Paleske A, Löffler H, Gassmann W, Hellriegel KP, Fülle HH, Lunscken C, Emmerich B, Pralle H, Pees HW, Pfreundschuh M, Bartels H, Koeppen KM, Schwerdtfeger R, Donhuijsen-Ant R, Mainzer K, Bonfert B, Köppler H, Zurborn KH, Ranft K, Thiel E, Heinecke A (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3: 1583–1589PubMedGoogle Scholar
  2. 2.
    Kartner N, Riordan JR, Ling V (1983) Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell Unes. Science 221: 1285–1288PubMedCrossRefGoogle Scholar
  3. 3.
    Kokenberg E, van der Steuyt K, Löwenberg B, Sonneveld P (1987) Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia. In: Büchner T, Schellong G, Hiddemann W, Urbanitz D, Ritter J (eds) Acute leukemias. Prognostic factors and treatment strategies. Springer, Berlin Heidelberg New York, pp 283–287 (Haematology and Blood Transfusion, vol 30)Google Scholar
  4. 4.
    Ling V, Thompson LH (1974) Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 83: 103–116PubMedCrossRefGoogle Scholar
  5. 5.
    Ma DDF, Scurr RD, Davey RA, Mackertich SM, Harman DH, Dowden G, Isbister JP, Bell DR (1987) Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukemia. Lancet 1: 135–137PubMedCrossRefGoogle Scholar
  6. 6.
    Pastan I, Gottesman M (1987) Multiple-drug resistance in human cancer. N Engl J Med 316: 1388–1393PubMedCrossRefGoogle Scholar
  7. 7.
    Powis G (1985) Anticancer drug pharmacodynamics. Cancer Chemother Pharmacol 14: 177–183PubMedCrossRefGoogle Scholar
  8. 8.
    Scheulen ME, Osieka R (1987) Increased activity of adriamycin against a human testicular cancer xenograft by cyclosporine A. Proc Am Assoc Cancer Res 28: 409Google Scholar
  9. 9.
    Scheulen ME, Hoensch H, Kappus H, Seeber S, Schmidt CG (1987) Positive correlation between decreased cellular uptake, NADPH-glutathione reductase activity and adriamycin resistance in Ehrlich ascites tumor lines. Arch Toxicol 60: 154–157PubMedCrossRefGoogle Scholar
  10. 10.
    Scheulen ME, Lennartz K, Heidrich T, Host G, Kramer B (1987) Determination of the cellular uptake of daunorubicin in human leukemia in vivo. Method of examination and first results. In: Büchner T, Schellong G, Hiddemann W, Urbanitz D, Ritter J (eds) Acute Leukemias. Prognostic factors and treatment strategies. Springer, Berlin Heidelberg New York, pp 298–301 (Haematology and blood transfusion, vol 30)Google Scholar
  11. 11.
    Speth PAJ, Linssen PCM, Boezeman JBM, Wessels HMC, Haanen C (1987) Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion. Cancer Chemother Pharmacol 20: 311–315PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • M. E. Scheulen
    • 1
  • B. Kramer
  • M. Skorzec
  • W. K. Reich
  1. 1.Department of Internal Medicine (Cancer Research), West German Tumor CenterUniversity of Essen Medical SchoolEssenGermany

Personalised recommendations